Douglas G. Cole - 06 Jun 2024 Form 4/A Insider Report for Sana Biotechnology, Inc. (SANA)

Reporting relationship: Director
Issuer ticker: SANA
Reported as of: 06 Jun 2024
Net transaction value: $0
SEC form: 4/A
Accepted by SEC: 15 Jul 2024, 16:11:44 UTC
Original report date: 07 Jun 2024
Prior SEC filing: 11 Aug 2023
Next SEC filing: 28 Jun 2024
Source filing: View source filing
Reporting owner signature: /s/ Julie Shah, Attorney-in-Fact for Douglas G. Cole

Key filing fact

Douglas G. Cole filed Form 4/A for Sana Biotechnology, Inc. (SANA) on 15 Jul 2024.

Key facts

This page summarizes Douglas G. Cole's Form 4/A filing for Sana Biotechnology, Inc. (SANA).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 15 Jul 2024, 16:11.

Change

Previous filing in this sequence was filed on 11 Aug 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4/A disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SANA transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +65,000
Change %
Price: $0.000000
Shares after: 65,000
Date: 06 Jun 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 65,000
Exercise price: $7.36
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

This Form 4/A is being filed to correct a clerical error with regard to the number of option shares acquired.

Footnote F2

The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 6, 2025 and (ii) immediately prior to the 2025 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date.